Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of MOR103 Administered Intravenously to Patients With Active Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Otilimab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors MorphoSys
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 06 Nov 2012 Results will be presented in a late-breaking abstract at the 2012 American College for Rheumatology Annual Meeting, according to a MorphoSys media release.
- 06 Nov 2012 Supplementary data to the 20 September 2012 results reported in a MorphoSys media release.